Analysts Set Embecta Corp. (NASDAQ:EMBC) PT at $11.00

Shares of Embecta Corp. (NASDAQ:EMBC) have been given a consensus recommendation of “Reduce” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.00.

A number of analysts have weighed in on the stock. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Weiss Ratings lowered shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd.

Embecta Trading Up 5.5%

Shares of NASDAQ EMBC opened at $5.59 on Friday. The company has a market cap of $316.73 million, a price-to-earnings ratio of 3.78 and a beta of 0.86. Embecta has a 12 month low of $2.77 and a 12 month high of $14.91. The stock has a 50-day moving average price of $4.61 and a two-hundred day moving average price of $5.41.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.29. The company had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s revenue was down 8.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, sell-side analysts predict that Embecta will post 1.84 earnings per share for the current year.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.7%. Embecta’s dividend payout ratio (DPR) is presently 2.70%.

Insider Buying and Selling at Embecta

In other Embecta news, CFO Jacob Elguicze acquired 20,000 shares of Embecta stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $4.67 per share, with a total value of $93,400.00. Following the completion of the purchase, the chief financial officer directly owned 309,139 shares in the company, valued at $1,443,679.13. This trade represents a 6.92% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeffrey Mann acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average cost of $4.99 per share, for a total transaction of $99,800.00. Following the completion of the purchase, the insider owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This trade represents a 8.23% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 70,000 shares of company stock worth $334,200 in the last three months. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Embecta

Large investors have recently modified their holdings of the company. Isthmus Partners LLC increased its position in shares of Embecta by 5.5% during the 1st quarter. Isthmus Partners LLC now owns 146,342 shares of the company’s stock valued at $1,294,000 after purchasing an additional 7,613 shares during the last quarter. Intech Investment Management LLC lifted its position in Embecta by 13.5% in the 4th quarter. Intech Investment Management LLC now owns 63,947 shares of the company’s stock worth $760,000 after buying an additional 7,616 shares during the last quarter. Royce & Associates LP boosted its stake in Embecta by 30.7% in the fourth quarter. Royce & Associates LP now owns 36,971 shares of the company’s stock worth $439,000 after buying an additional 8,682 shares in the last quarter. State of Wyoming boosted its stake in Embecta by 61.5% in the first quarter. State of Wyoming now owns 24,587 shares of the company’s stock worth $217,000 after buying an additional 9,366 shares in the last quarter. Finally, One Wealth Advisors LLC bought a new position in Embecta during the second quarter valued at approximately $33,000. 93.83% of the stock is currently owned by institutional investors and hedge funds.

About Embecta

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops and manufactures products designed to support insulin delivery and diabetes management. Its portfolio includes pen needles, insulin syringes, safety needles, lancets and other injection-related products used by people with diabetes and healthcare professionals.

The company also provides solutions intended to improve the safety, convenience and effectiveness of diabetes care, including connected and digital tools associated with insulin delivery.